Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:OREX
  • CUSIP: 68616410
  • Web: www.orexigen.com
Capitalization:
  • Market Cap: $27.47 million
  • Outstanding Shares: 15,431,000
Average Prices:
  • 50 Day Moving Avg: $2.15
  • 200 Day Moving Avg: $2.65
  • 52 Week Range: $1.65 - $5.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.32
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $63.39 million
  • Price / Sales: 0.43
  • Book Value: ($2.76) per share
  • Price / Book: -0.64
Profitability:
  • EBITDA: ($163,640,000.00)
  • Net Margins: -120.77%
  • Return on Equity: -824.15%
  • Return on Assets: -61.12%
Debt:
  • Debt-to-Equity Ratio: -4.08%
  • Current Ratio: 2.74%
  • Quick Ratio: 2.36%
Misc:
  • Average Volume: 155,378 shs.
  • Beta: 2.35
  • Short Ratio: 30.24
 

Frequently Asked Questions for Orexigen Therapeutics (NASDAQ:OREX)

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.82) EPS for the quarter, topping the Zacks' consensus estimate of ($2.40) by $0.58. The company had revenue of $23.36 million for the quarter, compared to analysts' expectations of $20 million. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 120.77%. Orexigen Therapeutics's revenue was up 199.9% on a year-over-year basis. During the same quarter last year, the business earned ($1.73) earnings per share. View Orexigen Therapeutics' Earnings History.

When will Orexigen Therapeutics make its next earnings announcement?

Orexigen Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Orexigen Therapeutics.

Who are some of Orexigen Therapeutics' key competitors?

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Independent Chairman of the Board
  • Michael A. Narachi, President, Chief Executive Officer, Director
  • Jason A. Keyes, Chief Financial Officer, Senior Vice President
  • Thomas R. Cannell, Chief Operating Officer, Executive Vice President, President - Global Commercial Products
  • Thomas P. Lynch, Executive Vice President, General Counsel, Secretary
  • Peter Flynn Ph.D., Senior Vice President, Head - Development, Regulatory Affairs and Safety
  • Louis C. Bock, Independent Director
  • Brian H. Dovey, Independent Director
  • David J. Endicott, Independent Director
  • Peter K. Honig M.D. M.P.H., Independent Director

How do I buy Orexigen Therapeutics stock?

Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orexigen Therapeutics' stock price today?

One share of Orexigen Therapeutics stock can currently be purchased for approximately $1.78.


MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Orexigen Therapeutics (NASDAQ:OREX)
Price Target History for Orexigen Therapeutics (NASDAQ:OREX)
Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00N/AView Rating Details
3/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$5.00 -> $2.00N/AView Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/29/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00N/AView Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldN/AView Rating Details
12/12/2015Bank of America CorporationReiterated RatingSellN/AView Rating Details
12/4/2015Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Earnings History by Quarter for Orexigen Therapeutics (NASDAQ OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($2.13)N/AView Earnings Details
8/8/2017Q2 2017($2.40)($1.82)$20.00 million$23.36 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.60)($4.67)$20.00 million$19.10 millionViewListenView Earnings Details
11/3/2016Q316($2.24)$1.12$8.17 million$7.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$51.80 million$0.86 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)$0.93 million$0.86 millionViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
Current Year EPS Consensus Estimate: $-9.37 EPS
Next Year EPS Consensus Estimate: $-5.59 EPS

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Orexigen Therapeutics (NASDAQ:OREX)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 39.66%
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stephen A. MogliaVPSell800$1.96$1,568.00View SEC Filing  
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Orexigen Therapeutics (NASDAQ:OREX)
Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
Source:
DateHeadline
seekingalpha.com logoOrexigen Therapeutics (OREX) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 7:13 AM
reuters.com logoBRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
www.reuters.com - October 14 at 6:32 AM
americanbankingnews.com logo Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Post Earnings of -$2.13 Per Share
www.americanbankingnews.com - October 13 at 4:36 PM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum
finance.yahoo.com - October 13 at 7:50 AM
finance.yahoo.com logoETFs with exposure to Orexigen Therapeutics, Inc. : October 11, 2017
finance.yahoo.com - October 12 at 7:55 AM
americanbankingnews.com logoOrexigen Therapeutics, Inc. (OREX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 12:40 PM
finance.yahoo.com logoBefore You Buy Orexigen Therapeutics Inc’s (OREX), You Should Consider This
finance.yahoo.com - October 5 at 7:15 PM
nasdaq.com logoOrexigen's (OREX) Contrave Sales Improving on Promotions - Nasdaq
www.nasdaq.com - September 30 at 5:46 PM
finance.yahoo.com logoOrexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®
finance.yahoo.com - September 29 at 5:39 PM
seekingalpha.com logoOrexigen Therapeutics (OREX) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 7:26 PM
reuters.com logoBRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍
www.reuters.com - September 28 at 1:50 AM
prnewswire.com logoOrexigen Therapeutics to Provide Business Update at the 2017 ... - PR Newswire (press release)
www.prnewswire.com - September 14 at 8:50 AM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 8:50 AM
americanbankingnews.com logoOrexigen Therapeutics (OREX) versus CLEMENTIA PHARM (CMTA) Critical Contrast
www.americanbankingnews.com - September 10 at 4:12 AM
seekingalpha.com logoOrexigen Therapeutics (OREX) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 7:05 AM
finance.yahoo.com logoETFs with exposure to Orexigen Therapeutics, Inc. : September 7, 2017
finance.yahoo.com - September 8 at 6:51 AM
finance.yahoo.com logoOrexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:04 AM
americanbankingnews.com logoOrexigen Therapeutics, Inc. (OREX) Issues Earnings Results
www.americanbankingnews.com - August 9 at 5:22 PM
seekingalpha.com logoOrexigen Therapeutics, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 9 at 6:08 AM
finance.yahoo.com logoOrexigen Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 6:08 AM
finance.yahoo.com logoOrexigen reports 2Q loss
finance.yahoo.com - August 9 at 6:08 AM
finance.yahoo.com logoEdited Transcript of OREX earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 6:08 AM
prnewswire.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel ... - PR Newswire (press release)
www.prnewswire.com - August 7 at 8:13 AM
finance.yahoo.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria
finance.yahoo.com - August 7 at 8:13 AM
americanbankingnews.com logo-$2.40 EPS Expected for Orexigen Therapeutics, Inc. (NASDAQ:OREX) This Quarter
www.americanbankingnews.com - July 31 at 12:28 PM
prnewswire.com logoOrexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 6:33 AM
finance.yahoo.com logoOrexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt
finance.yahoo.com - July 27 at 6:05 AM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 26 at 6:08 AM
benzinga.com logo15 Biggest Mid-Day Gainers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 21 at 5:49 AM
seekingalpha.com logoVivus Settlement Could Clue In Orexigen Investors - Seeking Alpha
seekingalpha.com - July 21 at 5:49 AM
finance.yahoo.com logoMartin Shkreli made gay investor uncomfortable with sex talk
finance.yahoo.com - July 19 at 1:08 AM
seekingalpha.com logoQuintiles IMS: A Novel Way To Invest In Biopharma
seekingalpha.com - July 18 at 7:05 AM
finance.yahoo.com logoA Martin Shkreli hedge fund account had 'negative 33 cents' in it when he claimed millions in assets
finance.yahoo.com - July 12 at 6:43 AM
finance.yahoo.com logoOrexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
finance.yahoo.com - July 11 at 6:26 AM
americanbankingnews.com logoOrexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.40 Per Share
www.americanbankingnews.com - July 7 at 8:54 AM
nasdaq.com logoPricing, Competition Remain Headwinds for Pharma in 2017 - Nasdaq
www.nasdaq.com - June 30 at 3:00 AM
nasdaq.com logoOrexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - June 16 at 8:35 AM
seekingalpha.com logoOrexigen Therapeutics (OREX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 6:16 PM
prnewswire.com logoOrexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 - PR Newswire (press release)
www.prnewswire.com - May 11 at 7:32 PM
reuters.com logoBRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67
www.reuters.com - May 9 at 6:40 PM
seekingalpha.com logoOrexigen Therapeutics, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 6:40 PM
marketbeat.com logoOrexigen reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
prnewswire.com logoOrexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch - PR Newswire (press release)
www.prnewswire.com - May 5 at 12:15 AM
benzinga.com logoExclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride - Benzinga
www.benzinga.com - May 2 at 4:51 PM
prnewswire.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for ... - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:51 PM
prnewswire.com logoResearch Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - April 28 at 12:33 AM
prnewswire.com logoOrexigen Therapeutics Announces New Drug Submission for Contrave© in Canada - PR Newswire (press release)
www.prnewswire.com - April 28 at 12:33 AM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 30 at 7:20 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - March 30 at 7:20 PM
prnewswire.com logoOrexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 - PR Newswire (press release)
www.prnewswire.com - March 30 at 5:47 AM

Social

Chart

Orexigen Therapeutics (OREX) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.